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Background and Purpose  A major concern with ocular myasthenia gravis (MG) is the po-
tential conversion to generalized MG. This study was conducted to determine if the repetitive 
nerve stimulation (RNS) test could predict the conversion from ocular to generalized MG.
Methods  The RNS test was conducted in a consistent manner on five muscles in the face and 
limbs in every patient. Subjects were divided into those who remained as ocular MG (ROMG 
group) and those who experienced conversion to generalized MG during follow-up (GOMG 
group).
Results  Conversion to generalized MG occurred in 24 (21.4%) of 112 MG patients with oc-
ular onset. The proportion of patients displaying abnormal decreases in responses in the tra-
pezius, abductor digiti minimi, or flexor carpi ulnaris muscles on the RNS test was higher in 
the GOMG group (p<0.001, p=0.002, and p<0.001, respectively). The Cox proportional-haz-
ards model revealed that an abnormal result on the RNS test was significantly associated with 
conversion to generalized MG [hazard ratio (HR)=3.13, 95% confidence interval (CI)=1.18–
8.32]. Notably, the HR was higher for abnormal results on the RNS test for the limb muscles, 
at 5.19 (95% CI=2.09–12.90).
Conclusions  An abnormal result on the RNS test, especially in the limb muscles, is an inde-
pendent predictor of the conversion from ocular to generalized MG. Applying the RNS test to 
limb muscles could be useful for predicting the conversion to generalized MG in patients with 
ocular onset.
Key Words   ocular myasthenia gravis, generalized myasthenia gravis, 
repetitive nerve stimulation test.
Initial Repetitive Nerve Stimulation Test 
Predicts Conversion of Ocular Myasthenia Gravis 
to Generalized Myasthenia Gravis
INTRODUCTION
Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction char-
acterized by fatigable muscle weakness.1,2 Reportedly 60–85% of MG patients initially 
present with ocular symptoms such as ptosis or diplopia, and a significant proportion of 
these patients subsequently progress to generalized MG.2-6 When managing MG patients 
with ocular onset, one of the main concerns is symptom conversion to a generalized form. It 
is well known that old age at onset, thymoma, and high acetylcholine receptor (AChR) anti-
body titer predict the conversion from ocular to generalized MG.7-10 
The repetitive nerve stimulation (RNS) test is a useful and the most commonly applied 
neurophysiological test for neuromuscular junction disorders including MG. Applying 
repetitive electrical stimulation to a motor nerve gradually depletes the releasable synap-
tic vesicles in presynaptic nerve terminals. In patients with MG, this can reduce the end-
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plate potential below the threshold required for the generation 
of muscle fiber action potentials. Theoretically, this decreased 
response is correlated with muscle fatigability. However, the 
role of the RNS test in predicting conversion to generalized 
MG among patients with ocular MG has been controversial. 
Some previous studies showed that the RNS test does not 
predict symptom conversion,11-13 whereas others have sug-
gested that the RNS test could predict the conversion to 
generalized MG. Hong et al.8 reported that an abnormal re-
sult on the RNS test is more frequently observed in patients 
who developed generalized MG than in those who remained 
as ocular MG. Other studies have also suggested that abnor-
mal results on the RNS test could predict symptom conver-
sion.10,14 However, in those studies the RNS test was not applied 
to all subjects and the investigated muscles differed between 
patients. Therefore, there are some limitations in interpreting 
the effect of the RNS test in predicting conversion to gener-
alized MG based on the current evidence.
This study aimed to determine whether an initial RNS test 
can predict the conversion to generalized MG in patients with 
ocular onset. The RNS test was conducted in a consistent man-
ner on five muscles of the limbs and face in every patient.
METHODS
Subject enrollment and data collection
This study had a retrospective cohort design. We retrospec-
tively reviewed the medical records of the patients with MG 
who visited the Department of Neurology at Severance Hos-
pital, Seoul, South Korea from June 2009 to December 2018. 
MG was diagnosed based on the presence of typical muscle 
weakness with fatigue, the results of the RNS and neostig-
mine challenge tests, and the results of serological tests in-
cluding AChR antibody and muscle-specific kinase (MuSK) 
antibody. Subjects were excluded when their symptoms were 
better explained by another disease. Patients were defined as 
ocular MG when symptoms were limited to the levator palpe-
brae, extraocular, and orbicularis oculi (OO) muscles at the 
time of diagnosis. 
Inclusion criteria were 1) diagnosed as ocular MG, 2) posi-
tivity in the neostigmine challenge test and/or in the serological 
test for autoantibodies, including AChR antibody and MuSK 
antibody, and 3) the RNS test conducted at five muscles [OO, 
nasalis (NA), abductor digiti minimi (ADM), flexor carpi ul-
naris (FCU), and trapezius (TR)] during the diagnostic work-
up. Patients with a follow-up duration of <6 months or age 
<15 years at the onset were excluded. 
Clinical features of the patients were collected by reviewing 
the medical records. Clinical information was collected on 
age, sex, age at symptom onset, age at diagnosis, initial thy-
mus status on chest computed tomography (CT), and history 
of thymectomy. If the patient’s symptoms remained ocular, 
information was collected on medications for MG adminis-
tered within 1 year from the diagnosis. Otherwise, information 
on medication administered before symptom conversion was 
collected in the patients who experienced symptom conver-
sion to generalized MG during the study period.
The Severance Hospital Institutional Review Board ap-
proved this study (approval no.: 4-2020-1712), and the study 
was conducted in accordance with the Declaration of Helsinki.
RNS testing
We analyzed the results of RNS tests performed during the 
diagnostic workup for MG. The RNS test was conducted us-
ing the following standard protocol in every patient: The base-
line compound muscle action potential (CMAP) was mea-
sured during supramaximal stimulation, and the postexercise 
CMAP was obtained after 20 seconds of maximal exercise.15 
Five low-frequency (3-Hz) RNSs were applied immediately 
after and at 1, 3, and 5 minutes after maximal exercise. During 
each stimulus train, the amplitude of the first CMAP and the 
lowest amplitude of the remaining CMAPs were calculated. A 
decrease in CMAP amplitude in any stimuli train of ≥10% 
was defined as abnormal.16 The RNS test was conducted in 
a consistent manner on the following five muscles in every 
patient: the OO, NA, ADM, FCU, and TR muscles. To min-
imize any immobilization problems, the stimulator was se-
cured with tape during the test. The test was performed on 
the more-affected side if the ocular symptom distribution was 
asymmetric. Patients who responded abnormally on the RNS 
test for any muscle were classified as the RNS-test-positive 
group, while other patients were classified as the RNS-test-
negative group.
Symptom conversion to generalized MG
All of the included subjects only had ocular symptoms includ-
ing diplopia and/or ptosis at the time of diagnosis. A thorough 
neurological examination was conducted by two neurologists 
during the diagnostic workup, which did not detect muscle 
weakness other than in the levator palpebrae, extraocular, and 
OO muscles. Symptom conversion to generalized MG was 
defined as the progression of weakness to an oropharyngeal, 
neck, limb, or respiratory muscle. The patients whose symp-
toms remained ocular during follow-up were classified as the 
remained as ocular MG (ROMG) group, and those who expe-
rienced conversion to generalized MG were classified as the 
generalized MG during follow-up (GOMG) group. 
Statistical analysis
Clinical and laboratory data were compared between the 
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ROMG and GOMG groups. Data are reported as number and 
percentage values for categorical variables, and as mean± SD 
or median and interquartile-range values for continuous vari-
ables depending on conformity with the normality assump-
tion. The Pearson chi-square test or Fisher’s exact test was used 
for categorical variables. Data that conformed to a normal dis-
tribution were compared between two groups using t-tests, 
while other data were compared using the Mann-Whitney U 
test. 
A Kaplan-Meier analysis was conducted to compare the cu-
mulative incidence of conversion to generalized MG between 
the RNS-test-positive and RNS-test-negative groups, and 
plots were compared using the log-rank test. The Cox propor-
tional-hazards model was used to estimate the effect of the ini-
tial RNS test on symptom conversion to generalized MG. Vari-
ables with p<0.05 in the univariate analyses were entered into 
the multivariate model to identify independent predictors of 
conversion to generalized MG. The results of the Cox propor-
tional-hazards model are reported as hazard ratios (HRs) with 
95% confidence intervals (95% CIs). Loss of follow-up was 
processed as censored data in the Cox proportional-hazards 
model. Statistical analyses were performed using SPSS for 
Windows (version 25, IBM Corp., Armonk, NY, USA). Dif-
ferences with a p value of <0.05 were regarded as significant. 
RESULTS
Patients 
A flow diagram of subject inclusion is displayed in Fig. 1. Dur-
ing the study period, 311 patients were newly diagnosed with 
MG, and 172 patients had only ocular symptoms at the time 
of the diagnostic workup. Then, 145 subjects for whom there 
was sufficient evidence of MG and who had also undergone 
the RNS test at the five muscles were selected. After exclud-
ing patients with a follow-up duration of <6 months or age 
<15 years at the onset, 112 patients with ocular MG were an-
alyzed in this study. The analyzed patients included 78 
(69.6%) with a positive result in the AChR antibody test (>0.5 
nmol/L) and no MuSK-antibody-positive MG. The follow-
up duration was 44±38 months, and 24 (21.4%) patients ex-
perienced conversion to generalized MG during follow-up. 
Thirteen (54.2%) patients showed limb weakness and seven 
(29.2%) had bulbar symptoms as the initial clinical feature of 
generalized MG. Neck weakness and dyspnea were reported 
for two patients each.
Comparison of clinical features between ROMG 
and GOMG groups
The clinical features of ROMG and GOMG groups are listed 
in Table 1. The median duration from the diagnosis of MG to 
the conversion to generalized MG in the GOMG group was 
15.9 months (interquartile range 5.2–30.8 months). The me-
dian follow-up time for patients in the ROMG group was 38.4 
months (interquartile range 19.0–89.0 months). The age at 
onset was significantly higher in the GOMG group (52.2±12.4 
years) than in the ROMG group (45.3±17.0 years, p=0.032). 
The AChR antibody titer was also higher in the GOMG group 
(9.1 nmol/L) than in the ROMG group (5.0 nmol/L, p<0.001), 
as was the proportion of patients who used oral prednisolone 
(58.0% vs. 33.3%, p=0.039). Among 24 patients who experi-
enced symptom conversion to generalized MG, 6 (25.0%) re-
ceived only corticosteroids and 2 (8.3%) received both corti-
costeroids and azathioprine. The median dose for eight patients 
who received prednisolone before conversion in the GOMG 
group was 25 mg (range 5–100 mg), and the median dose for 
51 patients who received prednisolone within 1 year from the 
diagnosis in the ROMG group was 20 mg (range 5–100 mg). 
The dose of prednisolone did not differ significantly between 
the two groups (p=0.858). The only immunosuppressive agent 
used was azathioprine. Two patients in the GOMG group and 
three patients in the ROMG group received azathioprine, at 
a dose of 100 mg for four patients and 150 mg for one patient.
There were no significant differences between the ROMG 
and GOMG groups in sex, duration from the onset of MG to 
Initially diagnosed as myasthenia gravis from July 2009 




 Only ocular symptom at the time of diagnostic 
  workup
Negative laboratory findings*
 Initial repetitive nerve stimulation test: 
  not performed at five muscles
Follow up duration <6 months (n=25)
Onset age <15 years (n=8)
Fig. 1. Patient enrollment. *Positivity in neostigmine challenge test 
and/or serological test for autoantibodies including acetylcholine re-
ceptor antibody and muscle-specific kinase antibody. 
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diagnosis, initial thymus status on chest CT, or proportion of 
patients who had a thymectomy. 
Comparison of the RNS test between ROMG and 
GOMG groups
The results of the RNS test in the ROMG and GOMG groups 
are summarized in Table 2. The proportion of patients dis-
playing decreased responses in the OO and NA muscles did 
not differ between the ROMG and GOMG groups. In con-
trast, the proportions of patients showing decreased responses 
in the TR, ADM, and FCU muscles were significantly higher 
in the GOMG group (37.5%, 16.7%, and 37.5%, respective-
ly) than in the ROMG group (8.0%, 0%, and 8.0%; p<0.001, 
p=0.002, and p<0.001, respectively). The proportion of sub-
jects showing a decreased response in at least one of the five 
muscles was also significantly higher in the GOMG group 
(75.0%) than in the ROMG group (38.6%, p=0.002). When 
the RNS results for the facial and limb muscles were analyzed 
separately, the RNS test results in the limb muscles (TR, ADM, 
and FCU) differed significantly between the ROMG and 
GOMG groups, whereas those in the facial muscles (OO and 
NA) did not. 
The magnitudes of the decreases are compared in Supple-
mentary Table 1 (in the online-only Data Supplement). Sim-
ilar to the comparison of the proportion of abnormal responses 
based on a threshold of 10%, the decreases in ADM, FCU, and 
TR muscles were significantly larger in the GOMG group than 
in the ROMG group (p=0.011, p=0.009, and p=0.044, respec-
tively). In contrast, the decreases in the OO and NA muscles 
did not differ between the ROMG and GOMG groups.
Table 1. Clinical features of patients in the ROMG and GOMG groups
ROMG (n=88) GOMG (n=24) p
Age at onset, years 45.3±17.0 52.2±12.4 0.032
Male 43 (50.0) 14 (58.3) 0.469
Duration from onset to MG diagnosis, months 2.9 [1.4–10.0] 1.9 [0.7–4.6] 0.082
Follow-up duration, months 38.4 [19.0–89.0] -
Duration from onset to conversion to generalized MG, months - 15.9 [5.2–30.8]
AChR-antibody positivity, >0.5 nmol/L 57 (66.3) 20 (83.3) 0.100
Titer of AChR antibody, nmol/L 5.0±3.7 9.1±3.6 <0.001
Positivity in neostigmine challenge test 62 (87.3) 19 (90.5) 0.725
Thymus on chest CT* 0.449
Normal 45 (57.0) 11 (45.8)
Thymic hyperplasia 20 (25.3) 6 (25.0)
Thymoma 14 (17.7) 7 (29.2)
Thymectomy 17 (19.3) 9 (37.5) 0.061
Thymoma confirmed by pathology 14 (15.9) 7 (29.2) 0.140
Treatment†
Pyridostigmine 83 (94.3) 24 (100) 0.227
Oral prednisolone 51 (58.0)   8 (33.3) 0.039
Use of immunosuppressive agent 3 (3.4) 2 (8.3) 0.291
Data are mean±SD, median [interquartile range], or n (%) values.
*Chest CT was performed in 79 patients in the ROMG group, †Medication administration within 1 year from the diagnosis in the ROMG group or before 
conversion in the GOMG group.
AChR: acetylcholine receptor, CT: computed tomography, GOMG: symptom conversion to generalized MG, MG: myasthenia gravis, ROMG: remained 
as ocular MG.







OO 20 (22.7) 9 (37.5) 0.143
NA 25 (28.4) 10 (41.7) 0.214
TR 7 (8.0) 9 (37.5) <0.001
ADM 0 (0) 4 (16.7) 0.002
FCU 7 (8.0) 9 (37.5) <0.001
At least one of OO, NA 31 (35.2) 13 (54.2) 0.092
At least one of TR, ADM, FCU 12 (13.6) 14 (58.3) <0.001
At least one of ADM, FCU 7 (8.0) 11 (45.8) <0.001
Any muscle 34 (38.6) 18 (75.0) 0.002
Data are n (%) values.
*≥10% decrease in compound muscle action potential after low-fre-
quency supramaximal RNS was defined as abnormal.
ADM: abductor digiti minimi, FCU: flexor carpi ulnaris, GOMG: symp-
tom conversion to generalized myasthenia gravis, NA: nasalis, OO: or-
bicularis oculi, RNS: repetitive nerve stimulation, ROMG: remained as 
ocular myasthenia gravis, TR: trapezius.
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Cumulative incidence and Cox proportional-hazard 
models for evaluating the predictive value 
of the RNS test
The cumulative incidence of conversion to generalized MG in 
the RNS-test-positive and RNS-test-negative groups as deter-
mined using the Kaplan-Meier method is displayed in Fig. 2. 
The incidence of symptom conversion to generalized MG was 
significantly higher in the RNS-test-positive group than in the 
RNS-test-negative group (log-rank test, p=0.001). The Cox 
proportional-hazards model was used to assess the effect of 
the initial RNS test on conversion to generalized MG. Table 3 
presents the results of the Cox proportional-hazards model 
for evaluating the predictive value of the RNS test. In the mul-
tivariate analyses, the AChR antibody titer (HR=1.11, 95% 
CI=1.02–1.22) and an abnormal response on the RNS test 
for any muscle (HR=3.13, 95% CI=1.18–8.32) were signifi-
cantly associated with symptom conversion from ocular MG. 
Additionally, for evaluating the impact of a reduction of the 
decreased response, these reductions relative to the baseline 
CMAP were divided into three groups: 10–20%, ≥20%, and 
≥30%. The HR in the Cox proportional-hazards models was 
higher when there was a larger decrease in the response. 
The response decrease on the RNS test was further ana-
lyzed by dividing muscles into specific muscle groups. Dif-
ferences of predictive values according to subgroup RNS test 
are presented in Table 4. Abnormal findings on the RNS test 
for the FCU and ADM limb muscles showed a higher HR of 
5.19 (95% CI=2.09–12.90). The effects of abnormal respons-
es on the RNS test for any muscle and for limb muscles were 
compared by constructing cumulative incidence curves us-



















0              25              50             75            100            125
Months after ocular symptom onset
Negative RNS test
Positive RNS test
Table 3. Results from Cox proportional-hazards models for variables associated with symptom conversion to generalized myasthenia gravis
Univariate p HR (95% CI) Multivariate* p HR (95% CI)
Sex 0.577 1.26 (0.56–2.84)
Age at onset 0.091 1.02 (0.99–1.05)
Titer of acetylcholine receptor antibody <0.001 1.17 (1.08–1.28) 0.023 1.11 (1.02–1.22)
Thymoma 0.159 1.89 (0.78–4.54)
Prednisolone use before conversion 0.036 0.40 (0.17–0.94) 0.110
Abnormal repetitive nerve stimulation test† 0.002   4.34 (1.72–10.97) 0.022 3.13 (1.18–8.32)
Response decrease of 10–20% 0.351 1.50 (0.64–3.52)
Response decrease ≥20% 0.001 4.15 (1.84–9.36)
Response decrease ≥30% <0.001   5.62 (2.31–13.67)
*Variables with p<0.05 in the univariate model were entered into the multivariate model, †Decreased response in at least one of the five muscles. 
CI: confidence interval, HR: hazard ratio. 
Table 4. Differences in predictive values according to subgroup RNS test in Cox proportional-hazards models 
Variable
Abnormal response 
in OO or NA
Abnormal response 
in TR, FCU, or ADM
Abnormal response 
in FCU or ADM
p HR (95% CI) p HR (95% CI) p HR (95% CI)
Titer of AChR antibody 0.005 1.14 (1.04–1.25)   0.053   0.046 1.09 (1.01–1.18)
Prednisolone use 0.111   0.396   0.364
Subgroup RNS test 0.364 <0.001 5.08 (2.07–12.52) <0.001 5.19 (2.09–12.90)
AChR: acetylcholine receptor, ADM: abductor digiti minimi, CI: confidence interval, FCU: flexor carpi ulnaris, HR: hazard ratio, NA: nasalis, OO: orbicu-
laris oculi, RNS: repetitive nerve stimulation, TR: trapezius.
Fig. 2. Cumulative incidence of conversion to generalized MG ac-
cording to the RNS test. The Kaplan-Meier survival curves show the 
cumulative incidence of conversion to generalized MG from ocular 
symptom onset according to the RNS test. The cumulative incidence 
of conversion to generalized MG was higher in the RNS-test-positive 
group than in the RNS-test-negative group (p=0.001). MG: myasthe-
nia gravis, RNS: repetitive nerve stimulation.
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DISCUSSION
The present findings demonstrate that the initial RNS test 
results can predict the conversion to generalized MG among 
patients with ocular MG. An abnormal decrease in the re-
sponse on the RNS test was observed more frequently in the 
GOMG group than in the ROMG group. The MG patients 
with ocular onset who displayed a decreased response on the 
RNS test had a 3.13-fold higher risk of conversion to gener-
alized MG compared with those with a normal result on the 
RNS test after adjusting other variables. Furthermore, abnor-
mal findings on the RNS test for limb muscles showed a high-
er HR. The decreased response observed in the limb muscles 
indicates the presence of subclinical weakness that might not 
be noticed by the patient or detected in a neurological exam-
ination.17 The RNS test, especially in limb muscles, could be 
considered in patients with ocular MG to predict conversion 
to generalized MG. 
When an abnormal electrophysiological response in limb 
muscles is detected in MG patients with only ocular symp-
toms, subtype classification of MG could be confusing. MG is 
currently classified into ocular and generalized forms based on 
clinical features rather than laboratory findings.1,2,18 Thus, MG 
patients whose symptoms remain ocular are classified as ocular 
MG even if an abnormal electrophysiological response in limb 
muscles is detected. A decreased response on the RNS test sug-
gests dysfunction of neuromuscular transmission in the tested 
muscle. A decreased response on the RNS test in limb mus-
cles can be assumed to indicate dysfunction of neuromuscular 
transmission. Therefore, the RNS test can detect this subclinical 
weakness among MG patients with only ocular symptoms. 
Among the 68 patients who exhibited no decreases in the re-
sponses of the OO and NA muscles on the RNS test, 7 (10.3%) 
showed an abnormally decreased response in limb muscles. 
This discrepancy may be attributed to differences between 
the tested muscles and the muscles causing ptosis and diplo-
pia. Major ocular symptoms such as ptosis and diplopia are 
caused by weakness in the levator palpebrae and extraocular 
muscles, whereas OO and NA—which are actually tested in 
the RNS test—are facial muscles. Those seven patients had 
normal facial muscle function or only mild eyelid closure 
weakness, and their quantitative MG score in tests performed 
simultaneously with an RNS test for facial muscles was 0 in 
five patients and 1 in two patients (data not shown). Well-pre-
served facial muscle function is presumed to the cause of nor-
mal responses for the OO and NA in the RNS test. These find-
ings suggest that performing RNS testing in the OO may be 
insufficient for evaluating neurotransmission in extraocular 
muscles. 
Several previous studies have found that decreased respons-
es were more frequent in patients who experienced conversion 
to generalized MG than in those who remained ocular.8,10,14 
However, several points should be considered when inter-
preting these data, especially regarding the results of the RNS 
test. In one study, the results were not statistically significant 
after adjusting for other variables.8 In addition, the muscles 
in which RNS tests were performed not selected in a consis-
tent manner, with TR and FCU muscles assessed in only 43% 
and 28% of the patients, respectively. In another study of pos-
itive RNS tests for independently predicting conversion to 
generalized MG, the RNS test was conducted in only 74% of 
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Positive RNS test in limb muscle
A  B  
Fig. 3. Cumulative incidence curves for the Cox proportional-hazards model. A: Cumulative incidence curves in the RNS-test-positive and RNS-
test-negative groups. The risk of conversion to generalized MG was 3.13-fold higher in the RNS-test-positive group than in the RNS-test-negative 
group after adjusting for acetylcholine receptor antibody titer and prednisolone administration (95% CI=1.18–8.32). B: Cumulative incidence curves 
for positive and negative RNS tests in limb muscles. The HR was higher for abnormal findings on the RNS test for limb muscles, at 5.19 (95% 
CI=2.09–12.90). CI: confidence interval, HR: hazard ratio, RNS: repetitive nerve stimulation.
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not provided.10 A recent study that showed that a positive RNS 
test for the facial muscle was an independent predictor only 
analyzed subjects with ocular MG under immunosuppres-
sive therapy.14 In addition, the RNS test was conducted mainly 
on the facial nerve, and applied to the ulnar nerve in only 34% 
of the patients. Since the RNS test was not conducted in every 
patient in a consistent manner, the possibility of selection 
bias exists. In the present study, five muscles were examined 
in a consistent manner in every patient and the RNS test was 
conducted after 20 seconds of maximal exercise in order to 
increase the test sensitivity.15,19 By applying this method the 
present study was able to focus on the usefulness of the initial 
RNS test in predicting symptom conversion from ocular MG.
In previous studies the proportion of patients who con-
verted from ocular to generalized MG ranged from 10% to 
60%.5,8-10,12,14 However, the rates of conversion only ranged 
from 10% to 23% in studies involving Asian patients, which is 
very similar to the 21.4% found in the present study. Con-
version from ocular to generalized MG usually occurs within 
2 years.8,20 In the present study, the median duration from 
onset to the conversion to generalized MG was 16 months. A 
higher AChR antibody titer was associated with conversion to 
generalized MG both in the present and previous studies.7,8,21 
The proportion of patients who initially took oral predniso-
lone was higher in the ROMG group than in the GOMG 
group. Although there were no significant results after adjust-
ing for other variables in the Cox proportional-hazards mod-
el, previous studies found a trend of immunosuppressive ther-
apy reducing the rate of conversion of ocular to generalized 
MG.8,11 
In contrast to previous studies,8,10,20 thymic histology was 
not significantly associated with conversion to generalized 
MG in the present study. This discrepancy may have been due 
to the times of thymectomy and prednisolone administration 
after surgery in this study. Fourteen of 21 subjects who had 
thymoma had not converted to generalized MG during fol-
low-up. Among them, 12 patients had undergone thymecto-
my within 3 months of their MG diagnosis, and another 2 
patients received surgery before their MG diagnosis. In addi-
tion, 6 of these 14 patients were treated with prednisolone be-
fore and after thymectomy. In a previous study that showed 
that the presence of thymoma predicts conversion to gener-
alized MG from ocular MG, the median duration from 
symptom onset to thymectomy was 12 months.20 Another 
two studies did not provide information about the time inter-
val between symptom onset and thymectomy.8,10 It is thought 
that early removal of thymoma and prednisolone adminis-
tration may have prevented symptom progression. Moreover, 
we could not find data on anterior mediastinum radiological 
evaluations or imaging for nine patients in the ROMG group, 
which could also have impacted the statistical results. 
The present study was subject to several limitations. First, 
this study was conducted at a single tertiary hospital and so 
there may have been selection bias for more-severe ocular MG. 
Additionally, our exclusion criterion of a follow-up period of 
shorter than 6 months could also have caused selection bias, 
which might have influenced the conversion rate to gener-
alized MG and other associated risk factors. Second, some 
errors may have been present due to the inherent nature of 
the RNS test. Immobilization can cause pseudofacilitation 
and reduce decreases in the responses, especially in the TR 
muscle, and is the most difficult problem when performing 
the RNS test.22 However, the RNS test was applied in a con-
sistent manner throughout the study period, and so it is un-
likely that this error markedly affected the analyses. Third, 
since this study had a retrospective design, it is difficult to be 
certain that the patients initially had only ocular symptoms. 
The rate of symptom conversion to generalized MG could 
have been either overestimated or underestimated. It would 
be interesting to prospectively investigate the conversion of 
ocular to generalized MG using a combination of clinical 
symptoms and MG-specific scales. Finally, the sample was 
too small to identify other risk factors for symptom conver-
sion to generalized MG. Previous studies with large samples 
revealed that AChR-antibody positivity, presence of thymo-
ma, and corticosteroid use were risk factors for conversion to 
generalized MG.8-10,20 In the present study, the proportion of 
patients taking prednisolone was significantly higher in the 
ROMG group, but this difference was not statistically signif-
icant after adjusting for other variables in the Cox proportion-
al-hazards model. The proportions of AChR-antibody posi-
tivity and presence of thymoma were also higher in the GOMG 
group than in the ROMG group, but the differences did not 
reach statistical significance. Considering the above factors, 
discrepancies from previous studies may have be due to the 
small sample in this study. 
In conclusion, this study has revealed that the RNS test 
can predict symptom conversion from ocular MG to gener-
alized MG. An abnormal RNS test for the limb muscles had 
a greater predictive value. Therefore, applying an RNS test to 
the limb muscles could be beneficial for predicting the con-
version of ocular MG to generalized MG. We suggest that 
the RNS test including limb muscles should be performed 
even in MG patients with only ocular symptoms. 
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